Canada-based Valeant Pharmaceuticals Inc. (NYSE: VRX) has raised its offer for Allergan Inc. (NYSE: AGN) for the second time this week. The latest offer, announced just minutes ago includes $72 a share and 0.83 shares of Valeant common stock for each share of Allergan.
Just two days ago Valeant raised its offer by $10 a share, from $48.30 to $58.30. The stock portion has remained constant.
Pershing Square Capital Managment, Allergan’s largest shareholder has agreed to elect only stock in Valeant as payment for its 9.7% stake in the Botox maker. Pershing Square’s CEO, Bill Ackman, has agreed to exchange each of the firm’s Allergan shares for 1.22659 shares of Valeant. Ackman said he called Valeant’s CEO this morning and “offered to give up $600 million of value to other Allergan shareholders and exchange our shares for Valeant stock if Valeant were prepared to increase its offer to other Allergan shareholders.”
Allergan has not responded to Valeant’s offer, but the stock is responding by rising nearly 5% to $166.01 in a 52-week range of $81.33 to $170.05.
NVIDIA has returned 250-fold in the past 10 years as artificial intelligence took off.
But if you missed out on NVIDIA’s historic run, your chance to see life-changing profits from AI isn’t over.
The 24/7 Wall Street Analyst who first called NVIDIA’s AI-fueled rise in 2009 just published a brand-new research report named “The Next NVIDIA.”
The report outlines key breakthroughs in AI and the stocks ready to dominate the next wave of growth. The report is absolutely free. Simply enter your email below
By providing your email address, you agree to receive communications from us regarding website updates and other offerings that may be of interest to you.
You have the option to opt-out of these emails at any moment. For more information, please review our Disclaimer and Terms of Use.